Switch to:

Denali Therapeutics Cash-to-Debt

: 6.86 (As of Sep. 2019)
View and export this data going back to 2017. Start your Free Trial

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Denali Therapeutics's cash to debt ratio for the quarter that ended in Sep. 2019 was 6.86.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Denali Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Sep. 2019.

NAS:DNLI' s Cash-to-Debt Range Over the Past 10 Years
Min: 6.75   Max: No Debt
Current: 6.86

6.75
No Debt

During the past 4 years, Denali Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 6.75. And the median was No Debt.

NAS:DNLI's Cash-to-Debt is ranked lower than
55% of the 1166 Companies
in the Biotechnology industry.

( Industry Median: 9.81 vs. NAS:DNLI: 6.86 )

Denali Therapeutics Cash-to-Debt Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

* Premium members only.

Denali Therapeutics Annual Data
Dec15 Dec16 Dec17 Dec18
Cash-to-Debt No Debt No Debt No Debt No Debt

Denali Therapeutics Quarterly Data
Dec15 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Cash-to-Debt Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only No Debt No Debt 6.80 6.75 6.86

Competitive Comparison
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap.


Denali Therapeutics Cash-to-Debt Distribution

* The bar in red indicates where Denali Therapeutics's Cash-to-Debt falls into.



Denali Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Denali Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2018 is calculated as:

Denali Therapeutics had no debt.

Denali Therapeutics's Cash to Debt Ratio for the quarter that ended in Sep. 2019 is calculated as:

Denali Therapeutics had no debt.

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.


Denali Therapeutics  (NAS:DNLI) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


Denali Therapeutics Cash-to-Debt Related Terms


Denali Therapeutics Cash-to-Debt Headlines

No Headline

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)